SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss ...
On a per-share basis, the Vancouver, British Columbia-based company said it had net income of 14 cents. Earnings, adjusted for restructuring costs and non-recurring costs, were 21 cents per share.
"This quarter we have made progress against our key objectives and have seen meaningful progress on our Gen 2 R1 cost structure due to the new technologies incorporated into the vehicle and ...
Results that may be inaccessible to you are currently showing.